series-b
Stage
4
Investors
About
Azafaros develops therapeutic agents for the treatment of rare metabolic disorders, specifically lysosomal storage disorders, through oral administration of aza-sugar compounds. Their lead program, nizubaglustat, targets neurological symptoms in conditions like GM1/GM2 gangliosidoses and Niemann-Pick type C disease.
Explore Azafaros's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.